Please note: The information displayed on this page might be outdated.
Medigene AG: Medigene AG is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative, cellular therapies to target various types and stages of cancer with candidates in clinical and pre-clinical development. Medigene concentrates on the development of personalized T cell-based immunotherapies.

Medigene (MDG1-ETR): US$209m MC
TCR-based I-O approach

Key Updates:
• (May 2019): bluebird bio (BLUE) announced initiation of new program in solid tumors focusing on MAGE-A4; BLUE mgmt presented PC data combining MDG’s TCR w bluebird’s TGFβ signal converter blocking tumor microenv’t immunosuppressive signals. In contrast to NY-ESO1 TCRs, MDG’s mAGE-A4 TCR led to complete tumor elimination in mice. Ph 1 to start 2020.
• (April 2019): Granted Cytovant (Roivant co) exclusive licenses to Medigene's T cell (NY-ESO-1) + DC vax (WT-1 & PRAME) across E Asia; collab for TCRs in 2 additional tgts. MDG: $10m upfront; devt, reg, and comml milestones up to $1b
• (Feb 2019): Initiated dosing in 1st TCR clinical trial for MDG1011 (target: PRAME; indications: AML, MDS, MM)
• (Dec 2018): Interim (1-yr) data from 20 pt Ph I/II DC vax trial: OS: 89%, PFS: 60% - final data YE 2019
• (May 2018) Expanded alliance w bluebird; # of tgt antigen/MHC restriction combos for TCR candidate discovery expanded from 4 to 6. Rec’d additional payment of $8M; $250M potential milestone payments/TCR program + tiered royalties

Upcoming Milestones:
• YE: Final readout (2-year treatment): Ph 1/2 20-pt DC vaccine trial in AML
• 2020: Ph 1 trial initiation w/ bluebird bio in 2020; progress expected across other discovery targets
• Continue dosing patients in MDG1011 Ph 1/2 12-pt TCR trial (target: PRAME; indications: AML, MDS, MM). ~ 5 additional centers in Germany to open recruitment
• Initiate dosing in 2nd TCR clinical trial (target: MAGE-A1; indication: MM); collab w/MDC & Charite
• Study start for second own TCR clinical trial with MDG1021 sched for 2020 (target: HA-1; indication: post-HSCT relapse)
Based in...
Clinical Stage
Phase l or ll
Disease Space
Immunotherapy, Oncology
Europe, Public
Market Cap
100MM - 500MM
Therapeutic Modalities
Antibodies, Cell Therapy
Lochhamer Str. 11
Planegg-Martinsried, 82152

Company Participants at Oktoberfest 2019 Wall Street "On Tap"

  • Dr. Kai Pinkernell, Chief Medical Officer, Chief Developing Officer
  • Prof. Dr. Dolores J. Schendel, CEO

Top 10 Holders of MediGene AG

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
Aviva Investors Global Services Ltd. 4.90 1,203,456 5.46 Stakes 11/30/19
QVT Financial LP 4.37 1,072,879 4.87 Stakes 11/30/19
DWS Investment GmbH 0.77 190,000 0.86 Funds 7/31/20
Dimensional Fund Advisors LP 0.56 136,943 0.62 Funds 7/31/20
Santander Towarzystwo Funduszy Inwestycyjnych SA 0.53 129,385 0.59 Funds 6/30/20
Bayerische Vermögen AG 0.09 22,800 0.10 Funds 7/31/20
Andreas Meißner Vermögensmanagement GmbH 0.08 20,000 0.09 Funds 6/30/20
Dimensional Fund Advisors Ltd. 0.02 4,543 0.02 Funds 5/31/20
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2020 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.